King's College London

Research portal

Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives

Research output: Contribution to journalArticlepeer-review

Standard

Optimizing Therapies Using Therapeutic Drug Monitoring : Current Strategies and Future Perspectives. / Irving, Peter M.; Gecse, Krisztina B.

In: Gastroenterology, Vol. 162, No. 5, 04.2022, p. 1512-1524.

Research output: Contribution to journalArticlepeer-review

Harvard

Irving, PM & Gecse, KB 2022, 'Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives', Gastroenterology, vol. 162, no. 5, pp. 1512-1524. https://doi.org/10.1053/j.gastro.2022.02.014

APA

Irving, P. M., & Gecse, K. B. (2022). Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives. Gastroenterology, 162(5), 1512-1524. https://doi.org/10.1053/j.gastro.2022.02.014

Vancouver

Irving PM, Gecse KB. Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives. Gastroenterology. 2022 Apr;162(5):1512-1524. https://doi.org/10.1053/j.gastro.2022.02.014

Author

Irving, Peter M. ; Gecse, Krisztina B. / Optimizing Therapies Using Therapeutic Drug Monitoring : Current Strategies and Future Perspectives. In: Gastroenterology. 2022 ; Vol. 162, No. 5. pp. 1512-1524.

Bibtex Download

@article{cdcbcf084dad477999c9a860cce75e87,
title = "Optimizing Therapies Using Therapeutic Drug Monitoring: Current Strategies and Future Perspectives",
abstract = "Therapeutic drug monitoring (TDM) has emerged as a strategy for treatment optimization in inflammatory bowel diseases to maximize benefit and to reach more stringent, objective end points. Optimal drug concentrations in inflammatory bowel disease vary according to treatment target, disease phenotype, inflammatory burden, and timing of sampling during the treatment cycle. This review provides an update on TDM with biologic and oral small molecules, evaluates the role of reactive vs proactive TDM, and identifies the gaps in current evidence. In the future, adaptations to how we use TDM may contribute further to the goal of personalized treatment in patients with IBD.",
keywords = "Crohn's Disease, Inflammatory Bowel Diseases, Therapeutic Drug Monitoring, Ulcerative Colitis",
author = "Irving, {Peter M.} and Gecse, {Krisztina B.}",
note = "Funding Information: Conflicts of interest Peter M. Irving has received honoraria for speaking on behalf of AbbVie, BMS, Celgene, Celltrion, Falk Pharma, Ferring, Galapagos, Gilead, MSD, Janssen, Lilly, Pfizer, Takeda, Tillotts, Sapphire Medical, Sandoz, Shire, Warner Chilcott, and for acting in an advisory capacity to AbbVie, Arena, Boehringer-Ingelheim, BMS, Celgene, Celltrion, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Prometheus, Roche, Sandoz, Samsung Bioepis, Takeda, Topivert, VH2, Vifor Pharma, and Warner Chilcott, and has received research grants from Celltrion, Galapagos, MSD, Pfizer, and Takeda. Krisztina B. Gecse has received grants from Pfizer Inc and Celltrion, consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, and Takeda, and speaker's honoraria from Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda, and Tillotts. Funding PMI is supported by a grant from the Medical Research Council (MR/T005564/1). Funding Information: Conflicts of interest Peter M. Irving has received honoraria for speaking on behalf of AbbVie, BMS, Celgene, Celltrion, Falk Pharma, Ferring, Galapagos, Gilead, MSD, Janssen, Lilly, Pfizer, Takeda, Tillotts, Sapphire Medical, Sandoz, Shire, Warner Chilcott, and for acting in an advisory capacity to AbbVie, Arena, Boehringer-Ingelheim, BMS, Celgene, Celltrion, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Prometheus, Roche, Sandoz, Samsung Bioepis, Takeda, Topivert, VH2, Vifor Pharma, and Warner Chilcott, and has received research grants from Celltrion, Galapagos, MSD, Pfizer, and Takeda. Krisztina B. Gecse has received grants from Pfizer Inc and Celltrion, consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, and Takeda, and speaker{\textquoteright}s honoraria from Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda, and Tillotts. Funding Information: Funding PMI is supported by a grant from the Medical Research Council (MR/T005564/1). Publisher Copyright: {\textcopyright} 2022 AGA Institute",
year = "2022",
month = apr,
doi = "10.1053/j.gastro.2022.02.014",
language = "English",
volume = "162",
pages = "1512--1524",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "WB Saunders",
number = "5",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - Optimizing Therapies Using Therapeutic Drug Monitoring

T2 - Current Strategies and Future Perspectives

AU - Irving, Peter M.

AU - Gecse, Krisztina B.

N1 - Funding Information: Conflicts of interest Peter M. Irving has received honoraria for speaking on behalf of AbbVie, BMS, Celgene, Celltrion, Falk Pharma, Ferring, Galapagos, Gilead, MSD, Janssen, Lilly, Pfizer, Takeda, Tillotts, Sapphire Medical, Sandoz, Shire, Warner Chilcott, and for acting in an advisory capacity to AbbVie, Arena, Boehringer-Ingelheim, BMS, Celgene, Celltrion, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Prometheus, Roche, Sandoz, Samsung Bioepis, Takeda, Topivert, VH2, Vifor Pharma, and Warner Chilcott, and has received research grants from Celltrion, Galapagos, MSD, Pfizer, and Takeda. Krisztina B. Gecse has received grants from Pfizer Inc and Celltrion, consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, and Takeda, and speaker's honoraria from Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda, and Tillotts. Funding PMI is supported by a grant from the Medical Research Council (MR/T005564/1). Funding Information: Conflicts of interest Peter M. Irving has received honoraria for speaking on behalf of AbbVie, BMS, Celgene, Celltrion, Falk Pharma, Ferring, Galapagos, Gilead, MSD, Janssen, Lilly, Pfizer, Takeda, Tillotts, Sapphire Medical, Sandoz, Shire, Warner Chilcott, and for acting in an advisory capacity to AbbVie, Arena, Boehringer-Ingelheim, BMS, Celgene, Celltrion, Genentech, Gilead, Hospira, Janssen, Lilly, MSD, Pfizer, Pharmacosmos, Prometheus, Roche, Sandoz, Samsung Bioepis, Takeda, Topivert, VH2, Vifor Pharma, and Warner Chilcott, and has received research grants from Celltrion, Galapagos, MSD, Pfizer, and Takeda. Krisztina B. Gecse has received grants from Pfizer Inc and Celltrion, consultancy fees from AbbVie, Arena Pharmaceuticals, Galapagos, Gilead, Immunic Therapeutics, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, and Takeda, and speaker’s honoraria from Celltrion, Ferring, Janssen Pharmaceuticals, Novartis, Pfizer Inc, Samsung Bioepis, Takeda, and Tillotts. Funding Information: Funding PMI is supported by a grant from the Medical Research Council (MR/T005564/1). Publisher Copyright: © 2022 AGA Institute

PY - 2022/4

Y1 - 2022/4

N2 - Therapeutic drug monitoring (TDM) has emerged as a strategy for treatment optimization in inflammatory bowel diseases to maximize benefit and to reach more stringent, objective end points. Optimal drug concentrations in inflammatory bowel disease vary according to treatment target, disease phenotype, inflammatory burden, and timing of sampling during the treatment cycle. This review provides an update on TDM with biologic and oral small molecules, evaluates the role of reactive vs proactive TDM, and identifies the gaps in current evidence. In the future, adaptations to how we use TDM may contribute further to the goal of personalized treatment in patients with IBD.

AB - Therapeutic drug monitoring (TDM) has emerged as a strategy for treatment optimization in inflammatory bowel diseases to maximize benefit and to reach more stringent, objective end points. Optimal drug concentrations in inflammatory bowel disease vary according to treatment target, disease phenotype, inflammatory burden, and timing of sampling during the treatment cycle. This review provides an update on TDM with biologic and oral small molecules, evaluates the role of reactive vs proactive TDM, and identifies the gaps in current evidence. In the future, adaptations to how we use TDM may contribute further to the goal of personalized treatment in patients with IBD.

KW - Crohn's Disease

KW - Inflammatory Bowel Diseases

KW - Therapeutic Drug Monitoring

KW - Ulcerative Colitis

UR - http://www.scopus.com/inward/record.url?scp=85127241041&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2022.02.014

DO - 10.1053/j.gastro.2022.02.014

M3 - Article

C2 - 35167865

AN - SCOPUS:85127241041

VL - 162

SP - 1512

EP - 1524

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 5

ER -

View graph of relations

© 2020 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454